GlassScriptPhysician profile
Kristen S Cunic
NPI 1386991693
$3,344.03
in general payments reported to CMS, 2019-2025
30 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $162 · 2022: $1,017 · 2023: $1,584 · 2024: $401 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,165.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $551.80 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $534.39 | 2022-2023 | Mounjaro, Jardiance, Trulicity |
| Abbott Laboratories | $329.05 | 2022-2024 | Proclaim, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $271.74 | 2022-2025 | |
| Corcept Therapeutics | $197.10 | 2022-2023 | Korlym |
| Dexcom, INC. | $159.18 | 2022-2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $157.99 | 2021-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.90 | 2021-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $133.63 | 2023-2024 | |
| Abbvie INC. | $126.62 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $124.74 | 2021 | |
| Amgen INC. | $104.22 | 2023-2024 | Prolia, Evenity, Repatha |
| Sanofi-Aventis U.S. LLC | $68.95 | 2022-2023 | |
| Vifor Pharma, INC. | $52.79 | 2024-2025 | Veltassa |
| Alexion Pharmaceuticals, INC. | $39.35 | 2022-2023 | Strensiq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $36.47 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $34.67 | 2022 | |
| Xeris Pharmaceuticals, INC. | $30.90 | 2022-2023 | Gvoke Hypopen |
| Hydrofera LLC | $26.43 | 2023 | Hydrofera Blue |
| Solventum Corporation | $24.59 | 2024 | Promogran Prisma |
| Ascendis Pharma Endocrinology INC | $24.56 | 2023 | |
| Tersera Therapeutics LLC | $22.88 | 2022 | |
| Medtronic, INC. | $20.72 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.64 | 2024 | Jynarque |
| Kyowa Kirin, INC. | $18.54 | 2023 | Crysvita |
| Insulet Corporation | $18.12 | 2023 | Omnipod |
| Ultragenyx Pharmaceutical INC. | $18.05 | 2022 | |
| Boston Scientific Corporation | $15.98 | 2025 | Cds - Mct/Cem Monitoring |
| Lifescan, INC. | $14.09 | 2023 | |
| Ardelyx, INC. | $13.94 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Cunic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.